ODYSSEY COMBO II - Investigational agent outshines ezetimibe for lowering cholesterol

BARCELONA, Spain – Sunday 31 August: The investigational drug alirocumab significantly improved cholesterol levels compared to ezetimibe, when added to regular statin therapy in patients with high cholesterol and elevated risk of cardiovascular disease (CVD), according to the ODYSSEY COMBO II trial, presented as a Hot Line today at ESC Congress 2014.

Fuente : http://www.alphagalileo.org/ViewItem.aspx?ItemId=1...